Clinical Trial Update: Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy (DAPT) Improve Thrombotic Status in Acute Coronray Syndrome (ACS) ACS [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating whether very low-dose rivaroxaban added to dual antiplatelet therapy improves thrombotic status in acute coronary syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: East and North Hertfordshire NHS Trust | Conditions: Acute Coronary Syndrome | Phase 4 | Status: UNKNOWN